{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BTKi", "query": { "intervention": "BTKi" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 48, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BTKi&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T08:29:34.251Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07526597", "title": "Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Discontinuing Bruton tyrosine kinase inhibitors (BTKi) therapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2026-09", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-06T08:29:34.251Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07526597" }, { "nct_id": "NCT04978779", "title": "A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Non Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Richter Syndrome", "MYC Amplification", "MYC Overexpression", "MYC Translocation" ], "interventions": [ { "name": "VIP152", "type": "DRUG" }, { "name": "BTKi", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vincerx Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-12-16", "completion_date": "2023-05-26", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-09-06T08:29:34.251Z", "location_count": 4, "location_summary": "Cincinnati, Ohio • Columbus, Ohio • Dallas, Texas + 1 more", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04978779" }, { "nct_id": "NCT06466122", "title": "Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Kerry Rogers", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-11-07", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-09-06T08:29:34.251Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06466122" }, { "nct_id": "NCT04947319", "title": "Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Primary Central Nervous System Lymphoma", "Primary CNS Lymphoma" ], "interventions": [ { "name": "Tirabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ono Pharmaceutical Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2021-12-29", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-06T08:29:34.251Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04947319" }, { "nct_id": "NCT05170399", "title": "Vaccine Responses in Patients With B Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "AREXVY, ABRYSVO", "type": "DRUG" }, { "name": "PREVNAR 20", "type": "DRUG" }, { "name": "PNEUMOVAX 23", "type": "BIOLOGICAL" }, { "name": "Heplisav -B", "type": "BIOLOGICAL" }, { "name": "PREVNAR 13", "type": "BIOLOGICAL" }, { "name": "Shingrix", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 350, "start_date": "2022-09-14", "completion_date": "2036-11-15", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-06T08:29:34.251Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05170399" }, { "nct_id": "NCT07342478", "title": "ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "CLL / SLL", "CLL (Chronic Lymphocytic Leukemia)", "CLL, Refractory", "CLL, Relapsed", "SLL (Small Lymphocytic Lymphoma)", "SLL", "CLL", "CLL Progression" ], "interventions": [ { "name": "Rocbrutinib", "type": "DRUG" }, { "name": "Pirtobrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Newave Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 306, "start_date": "2026-04-23", "completion_date": "2030-07-30", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-06T08:29:34.251Z", "location_count": 6, "location_summary": "Skokie, Illinois • Bethesda, Maryland • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Skokie", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07342478" }, { "nct_id": "NCT05023980", "title": "A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loxo Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2021-09-23", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-09-06T08:29:34.251Z", "location_count": 5, "location_summary": "Los Angeles, California • Whittier, California • Coral Springs, Florida + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Brick", "state": "New Jersey" }, { "city": "Westbury", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05023980" }, { "nct_id": "NCT07711327", "title": "Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atrial Fibrillation (AF)", "Chronic Lymphocytic Leukemia", "Waldenstrom Macroglobulinemia", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "Tina Baykaner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2026-08", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-09-06T08:29:34.251Z", "location_count": 3, "location_summary": "Duarte, California • San Diego, California • Stanford, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07711327" }, { "nct_id": "NCT05788289", "title": "A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma", "MCL" ], "interventions": [ { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2023-03-14", "completion_date": "2024-08-01", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-09-06T08:29:34.251Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05788289" }, { "nct_id": "NCT07108998", "title": "Study of Epcoritamab as a Consolidation Therapy in CLL/SLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CLL/SLL", "CLL", "SLL", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Small Lymphocytic Lymphoma Variant", "Chronic Lymphocytic Leukemia Variants" ], "interventions": [ { "name": "Epcoritamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zulfa Omer", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2025-08-22", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-09-06T08:29:34.251Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07108998" } ] }